Safety Data of Oral JAK Inhibitors in Atopic Dermatitis

EP: 1.Oral JAK Inhibitors in Atopic Dermatitis

EP: 2.Oral JAK Inhibitors vs Other Systemic Treatments in Atopic Dermatitis

EP: 3.Candidates for Oral JAK Inhibitor Use in Atopic Dermatitis

EP: 4.Choosing Between Oral JAK Inhibitors in Atopic Dermatitis

Now Viewing

EP: 5.Safety Data of Oral JAK Inhibitors in Atopic Dermatitis

EP: 6.Patient Communication and Utilization of JAK Inhibitors in Atopic Dermatitis

Video content above is prompted by the following questions:

• Are there differences in safety data from clinical trials vs. real-world studies? What has been your clinical experience with abrocitinib and upadacitinib?
• Discuss your monitoring schedule for patients taking JAK inhibitors.
  • How do you modify your monitoring protocol according to patient characteristics and preferences?